Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round. Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The newly formed company, with headquarters in Seattle and Singapore, intends to use the proceeds from the Series A financing […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!